Personalized pharmacotherapy for Type 2 diabetes mellitus

Airani Sathananthan, Adrian Vella

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.

Original languageEnglish (US)
Pages (from-to)417-422
Number of pages6
JournalPersonalized Medicine
Volume6
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Type 2 Diabetes Mellitus
Drug Therapy
Genome-Wide Association Study
Pharmacogenetics
Pharmaceutical Preparations
Therapeutics

Keywords

  • OCT 1
  • Pharmacogenetics
  • Sulfonylureas
  • TCF7L2
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Molecular Medicine
  • Medicine(all)
  • Pharmacology

Cite this

Personalized pharmacotherapy for Type 2 diabetes mellitus. / Sathananthan, Airani; Vella, Adrian.

In: Personalized Medicine, Vol. 6, No. 4, 2009, p. 417-422.

Research output: Contribution to journalArticle

Sathananthan, Airani ; Vella, Adrian. / Personalized pharmacotherapy for Type 2 diabetes mellitus. In: Personalized Medicine. 2009 ; Vol. 6, No. 4. pp. 417-422.
@article{81c8a2b229464c63b59e5776ca74cb86,
title = "Personalized pharmacotherapy for Type 2 diabetes mellitus",
abstract = "Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.",
keywords = "OCT 1, Pharmacogenetics, Sulfonylureas, TCF7L2, Type 2 diabetes mellitus",
author = "Airani Sathananthan and Adrian Vella",
year = "2009",
doi = "10.2217/pme.09.3",
language = "English (US)",
volume = "6",
pages = "417--422",
journal = "Personalized Medicine",
issn = "1741-0541",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Personalized pharmacotherapy for Type 2 diabetes mellitus

AU - Sathananthan, Airani

AU - Vella, Adrian

PY - 2009

Y1 - 2009

N2 - Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.

AB - Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.

KW - OCT 1

KW - Pharmacogenetics

KW - Sulfonylureas

KW - TCF7L2

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=67949123280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67949123280&partnerID=8YFLogxK

U2 - 10.2217/pme.09.3

DO - 10.2217/pme.09.3

M3 - Article

AN - SCOPUS:67949123280

VL - 6

SP - 417

EP - 422

JO - Personalized Medicine

JF - Personalized Medicine

SN - 1741-0541

IS - 4

ER -